Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 10/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 4/20 | 0.52 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811048 | 0.95 | KEAP1 (0.62) | KEAP1GLP1RCALCR | |
| SCHEMBL30168767 | 0.89 | KEAP1 (0.59) | KEAP1GLP1RMAPK8MAPK9MAPK10 | |
| SCHEMBL29836276 | 0.87 | KEAP1 (0.57) | KEAP1GLP1RCALCRMAPK8MAPK9 | |
| SCHEMBL30168691 | 0.87 | KEAP1 (0.56) | KEAP1GLP1RC5AR1BECN1KDM1A | |
| SCHEMBL31182880 | 0.87 | CALCR (0.67) | GLP1RCALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL30168694 | 0.86 | KEAP1 (0.59) | KEAP1GLP1RBECN1KDM1AMAPK8 | |
| SCHEMBL30950134 | 0.86 | KEAP1 (0.66) | KEAP1GLP1RMAPK8MAPK9MAPK10 | |
| SCHEMBL30168734 | 0.86 | F2 (0.56) | KEAP1GLP1RBECN1KDM1A | |
| SCHEMBL30168693 | 0.86 | F2 (0.56) | KEAP1GLP1RBECN1KDM1A | |
| SCHEMBL30168702 | 0.86 | MAPK8 (0.56) | KEAP1GLP1RCALCRBECN1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | KEAP1 3572/4885GLP1R 2107/4885C5AR1 403/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | KEAP1 3572/4885GLP1R 2107/4885C5AR1 403/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | KEAP1 3592/4885GLP1R 1475/4885C5AR1 1431/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | KEAP1 2393/4885GLP1R 2834/4885C5AR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.